We are live on ! Find out more
CCXI icon

ChemoCentryx

Delisted

CCXI was delisted on the 19th of October, 2022.

115 hedge funds and large institutions have $354M invested in ChemoCentryx in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 29 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

106% more capital inflows, than outflows

Capital inflows: $48.4M | Capital outflows: $23.5M

41% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 29

15% more funds holding

Funds holding: 100 → 115 (+15)

4.24% more ownership

Funds ownership: 50.36% → 54.6% (+4.2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less call options, than puts

Call options by funds: $579K | Put options by funds: $691K

Holders
115
Holders Change
+15
Holders Change %
+15%
% of All Funds
2.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
29
Increased
41
Reduced
29
Closed
13
Calls
$579​K
Puts
$691​K
Net Calls
-⁠$112​K
Net Calls Change
+$163​K

CCXI Hedge Fund Activity: Q2 2018 in Review

115 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx (CCXI) for Q2 2018, worth a combined $354M — up 5.5% from $335M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CCXI positions and 13 closed out — a net gain of 16 holders — while 41 added to existing stakes and 29 trimmed.

The largest buyer was Carmignac Gestion, adding an estimated $7.61M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $6.26M sold.

  • 115 institutional investors held ChemoCentryx (CCXI) as of Q2 2018, up from 100 in Q1 2018.
  • Funds reported $354M of ChemoCentryx stock for Q2 2018, up 5.5% quarter-over-quarter.
  • 29 funds opened new ChemoCentryx positions in Q2 2018 and 13 closed out, a net change of +16 holders.
  • The largest ChemoCentryx buyer in Q2 2018 was Carmignac Gestion, an estimated $7.61M added.
  • The largest ChemoCentryx seller in Q2 2018 was T. Rowe Price Associates, an estimated $6.26M sold.

Based on aggregated 13F filings for Q2 2018.